mortality

Epidemiology of Multiple Myeloma in Novosibirsk (Siberian Federal District)

LYMPHOID TUMORS , , , , ,

NV Skvortsova1, TI Pospelova1, IB Kovynev1, GS Soldatova2, IN Nechunaeva3

1 Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation, 630091

2 Novosibirsk National Research State University, 2 Pirogova str., Novosibirsk, Russian Federation, 630090

3 Municipal Clinical Hospital No. 2 of Novosibirsk Region, Center of Hematology, 21 Polzunov str., Novosibirsk, Russian Federation, 630051

For correspondence: Nataliya Valer’evna Skvortsova, MD, PhD, 52 Krasnyi pr-t, Novosibirsk, Russian Federation, 630091; Tel.: +7(905)955-59-91; e-mail: nata_sk78@mail.ru.

For citation: Skvortsova NV, Pospelova TI, Kovynev IB, et al. Epidemiology of Multiple Myeloma in Novosibirsk (Siberian Federal District). Clinical oncohematology. 2019;12(1):86–94.

DOI: 10.21320/2500-2139-2019-12-1-86-94

ABSTRACT

Aim. To analyze major epidemiological parameters of multiple myeloma, i.e. registered incidence, prevalence, mortality, and survival in Novosibirsk, megalopolis in Siberian Federal District.

Materials & Methods. The study covered medical records of 335 patients with newly diagnosed multiple myeloma (MM) treated from January 1, 2006 to December 31, 2016 at the Center of Hematology in Novosibirsk. Median age was 67 years (range 30–89), the trial enrolled 218 (65 %) women and 117 (35 %) men.

Results. Over the last decade the mean registered MM incidence in Novosibirsk increased by 1.6 times, and MM prevalence increased by 4.9 times. These parameters correspond to 2.4 and 13.8 per 100,000 population per year, respectively, with the linear trend of growth which demonstrates not only the increased number of patients with newly diagnosed MM, but the increased longevity of them. MM incidence and prevalence parameters are significantly higher in women than in men, which most probably can be accounted for by specific administrative factors in the Novosibirsk region. Yearly mortality of MM patients decreased from 28.3 % to 8.2 % with a negative linear trend over the entire analyzed period, which is most likely to be associated with availability of new drugs and transplantation procedures.

Conclusion. The obtained epidemiological data will enable to plan the provision of timely and effective care for MM patients and to elaborate a system of judicious allocation of costly equipment and drugs.

Keywords: multiple myeloma, epidemiology, registered incidence, prevalence, mortality, survival.

Received: September 24, 2018

Accepted: December 27, 2018

Read in PDF 

REFERENCES

  1. Менделеева Л.П., Вотякова О.М., Покровская О.С. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология. 2016;61(1, прил. 2):1–24. doi: 10.18821/0234-5730-2016-61-1(Прил.2).

    [Mendeleeva LP, Votyakova OM, Pokrovskaya OS, et al. National clinical guidelines on diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2016;61(1, Suppl 2):1–24. doi: 10.18821/0234-5730-2016-61-1(Прил.2). (In Russ)]

  2. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20(4):637–64. doi: 10.1016/j.beha.2007.08.001.

  3. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116(25):5501–6. doi: 10.1182/blood-2010-07-298760.

  4. de Queiroz Crusoe E, Marinho da Silva AM, Agareno J, et al. Multiple myeloma: a rare case in an 8-year-old child. Clin Lymph Myel Leuk. 2015;15(1):e31–3. doi: 10.1016/j.clml.2014.08.004.

  5. Аль-Ради Л.С., Белоусова И.Э., Барях Е.А. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Современная онкология. 2013;Экстравыпуск:6–102.

    [Al’-Radi LS, Belousova IE, Baryakh EA, et al. Russian clinical guidelines on diagnosis and treatment of lymphoproliferative disorders. Sovremennaya onkologiya. 2013;Special Issue:6–102. (In Russ)]

  6. Ковынев И.Б., Поспелова Т.И., Агеева Т.А. и др. Частота и структура неходжкинских злокачественных лимфом в Новосибирске, НСО и городах Сибирского федерального округа. Бюллетень Сибирского отделения РАМН. 2006;26(4):175–81.

    [Kovynev IB, Pospelova TI, Ageeva TA, et al. Incidence and structure of non-Hodgkin’s malignant lymphomas in Novosibirsk, Novosibirsk Region, and cities of Siberian Federal District. Byulleten’ Sibirskogo otdeleniya RAMN. 2006;26(4):175–81. (In Russ)]

  7. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignance. Semin Oncol. 2016;43(6):676–81. doi: 10.1053/j.seminoncol.2016.11.004.

  8. Becker N. Epidemiology of multiple myeloma. Rec Res Cancer Res. 2011;183:25–35. doi: 10.1007/978-3-540-85772-3_2.

  9. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2007;57(1):43–66. doi: 10.3322/canjclin.57.1.43.

  10. Ruzafa JC, Merinopoulou E, Baggaley RF, et al. Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model. Pharmacoepidemiol Drug Saf. 2016;25(8):871–9. doi: 10.1002/pds.3927.

  11. Rosenberg PS, Barker KA, Anderson WF. Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood. 2015;125(2):410–2. doi: 10.1182/blood-2014-10-609461.

  12. Yamabe K, Inoue S, Hiroshima C. Epidemiology and burden of multiple myeloma in Japan: a systematic review. Value Health. 2015;18(7):A449. doi: 10.1016/j.jval.2015.09.1129.

  13. Hong J, Lee JH. Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med. 2016;31(5):820–34. doi: 10.3904/kjim.2015.408.

  14. Chen XC, Chen XZ. Epidemiological differences in haematological malignancies between Europe and China. Lancet Oncol. 2014;15(11):е471–2. doi: 10.1016/S1470-2045(14)70441-3.

  15. Chen JH, Chung CH, Wang YC, et al. Prevalence and mortality-related factors of multiple myeloma in Taiwan. PLoS One. 2016;11(12):e0167227. doi: 10.1371/journal.pone.0167227.

  16. Лучинин А.С., Семочкин С.В., Минаев Н.В. и др. Эпидемиология множественной миеломы по данным анализа популяционного регистра Кировской области. Онкогематология. 2017;12(3):50–6. doi: 10.17650/1818-8346-2017-12-3-50-56.

    [Luchinin AS, Semochkin SV, Minaeva NV, et al. Epidemiology of Multiple Myeloma According to the Кirov Region Population Registers. Oncohematology. 2017;12(3):50–6. doi: 10.17650/1818-8346-2017-12-3-50-56. (In Russ)]

  17. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993–9. doi: 10.1200/jco.2006.09.0100.

  18. Brenner H, Gondos A, Pulte D. Recent major improvements in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521–6. doi: 10.1182/blood-2007-08-104984.

  19. Schaapveld M, Visser O, Siesling S, et al. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46(1):160–9. doi: 10.1016/j.ejca.2009.07.006.

  20. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20. doi: 10.1182/blood-2007-10-116129.

  21. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 1975–2007. Available from: http://seer.cancer.gov/csr/1975_2007/ (accessed 6.11.2018).

  22. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена, 2017. 250 с.

    [Kaprin AD, Starinskii VV, Petrova GV. Zlokachestvennye novoobrazovaniya v Rossii v 2015 g. (zabolevaemost’ i smertnost’). (Malignant neoplasms in Russia in 2015: incidence and mortality.) Moscow: PA Herzen MNIOI Publ.; 2017. 250 p. (In Russ)]

  23. Володичева Е.М., Воробьева Т.В., Пивник А.В. Анализ заболеваемости множественной миеломой в Тульской области. Проблемы гематологии и переливания крови. 2000;4:31–4.

    [Volodicheva EM, Vorob’eva TV, Pivnik AV. Analysis of multiple myeloma incidence in the Tula region. Problemy gematologii i perelivaniya krovi. 2000;4:31–4. (In Russ)]

  24. Капорская Т.С., Киселев И.В., Силин А.П. Анализ заболеваемости множественной миеломой в Иркутской области. Сибирский медицинский журнал. 2006;66(8):65–7.

    [Kaporskaya TS, Kiselev IV, Silin AP. Analysis of multiple myeloma incidence in the Irkutsk region. Sibirskii meditsinskii zhurnal. 2006;66(8):65–7. (In Russ)]

  25. Гильфанова Л.Р., Крисанкова К.А. Новосибирская агломерация: проблемы и перспективы развития. Новая наука: теоретический и практический взгляд. 2017;1(4):116–9.

    [Gil’fanova LR, Krisankova KA. Novosibirsk agglomeration: challenges and prospects for the development. Novaya nauka: teoreticheskii i prakticheskii vzglyad. 2017;1(4):116–9. (In Russ)]

  26. Региональная база статистических данных «Новосибирская область» [электронный документ]. Доступно по: http://www.novosibstat.gks.ru. Ссылка активна на 6.11.2018.

    [Regional statistical database “Novosibirsk region” [Internet]. Available from: http://www.novosibstat.gks.ru. (accessed 6.11.2018) (In Russ)]

  27. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73. doi: 10.1038/sj.leu.2404284.

  28. Pulte D, Jansen L, Castro FA, et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol. 2015;171(2):189–96. doi: 10.1111/bjh.13537.

  29. Лосева М.И., Поспелова Т.И., Гавалова Р.Ф. и др. Полиорганная патология у больных гемобластозами в отдаленном периоде лечения. Терапевтический архив. 1999;71(7):39–42.

    [Loseva MI, Pospelova TI, Gavalova RF, et al. Multiple organ failure in patients with tumors of hematopoietic tissue during long-term follow-up. Terapevticheskii arkhiv. 1999;71(7):39–42. (In Russ)]

Epidemiology of Chronic Myeloid Leukemia in the Republic of Bashkortostan

MYELOID TUMORS , , , ,

NR Ryabchikova, GSh Safuanova, VI Nikulicheva

Bashkir State Medical University, 3 Lenina str., Ufa, Russian Federation, 450008

For correspondence: Prof. Guzyal’ Shagbanovna Safuanova, MD, PhD, 3 Lenina str., Ufa, Russian Federation, 450008; Tel.: +7(927)639-03-73; e-mail: safuanova@bk.ru

For citation: Ryabchikova NR, Safuanova GSh, Nikulicheva VI. Epidemiology of Chronic Myeloid Leukemia in the Republic of Bashkortostan. Clinical oncohematology. 2018;11(4):349–53.

DOI: 10.21320/2500-2139-2018-11-4-349-353

ABSTRACT

Background. The planning of therapeutic, diagnostic, and preventive medical care for chronic myeloid leukemia (CML) patients implies the need of not only maintaining patient registries, but also conducting epidemiologic studies in each geographical area.

Aim. To study and analyze CML epidemiological indicators over the last 15 years in the Republic of Bashkortostan for the purposes of evaluation and rational planning of specialized medical care for CML patient population.

Materials & Methods. The incidence, prevalence, and mortality of CML patients of all age groups in the period of 2000–2016 was analyzed in the Republic of Bashkortostan.

Results. The analysis of epidemiological indicators over the period of 2000–2016 showed that the incidence of the disease in the Republic of Bashkortostan was increasing. Within the last 8 years the prevalence rate even quadrupled which is clearly connected with improved detectability of Ph-chromosome and/or BCR-ABL gene, creation and maintenance of CML patient registry since 2008, introduction of treatment using tyrosine kinase inhibitors resulting also in increase in life expectancy. Mortality rates are reported to have a tendency of decrease over the period under study.

Conclusion. Key epidemiological indicators of CML in the Republic of Bashkortostan are comparable with the data of international and Russian researchers. The results obtained can be used for comparative studies and improvement of specialized medical care for CML patients.

Keywords: chronic myeloid leukemia, epidemiology, incidence, prevalence, mortality.

Received: April 9, 2018

Accepted: August 3, 2018

Read in PDF 

REFERENCES

  1. Абдулкадыров К.М., Абдуллаев А.О., Авдеев Л.Б. и др. Федеральные клинические рекомендации по диагностике и терапии хронического миелолейкоза. Вестник гематологии. 2013;9(3):4–40.

    [Abdulkadyrov KM, Abdullaev AO, Avdeev LB, et al. Fedеral clinical guidelines on diagnosis and treatment of chronic myeloid leukemia. Vestnik gematologii. 2013;9(3):4–40. (In Russ)]

  2. Волкова С.А., Ковалишена О.В., Прыткова М.В. и др. Эпидемиологическое исследование хронического миелолейкоза у взрослого населения Нижегородской области за период 1980–2003 гг. Гематология и трансфузиология. 2005;50(2):8–13.

    [Volkova SA, Kovalishena OV, Prytkova MV, et al. Epidemiological studies of chronic myeloid leukemia in adults of the Nizhny Novgorod region in 1980–2003. Gematologiya i transfuziologiya. 2005;50(2):8–13. (In Russ)]

  3. Виноградова О.Ю., Куликов С.М., Куцев С.М. и др. Проблемы организации лечения хронического миелолейкоза в России. Клиническая онкогематология. 2011;4(4):292–7.

    [Vinogradova OYu, Kulikov SM, Kutsev SM, et al. Issues of organizing the treatment of chronic myeloid leukemia in the Russian Federation. Klinicheskaya onkogematologiya. 2011;4(4):292–7. (In Russ)]

  4. Pasguini R, Cortes J, Kantarjian HM, et al. A worldwide observational registry collecting longitudinal data on management of chronic myeloid leukemia patients (The WORLD CML Registry)-2nd Annual interim analysis. Blood. 2010;116(21):2292.

  5. Juliusson G, Lazarevic V, Horsterdt A, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–9. doi: 10.1182/blood-2011-12-379008.

  6. Варшавский А.В. Клинико-эпидемиологическая характеристика гемобластозов в Республике Башкортостан: Автореф. дис.… канд. мед. наук. Уфа, 2011.

    [Varshavskii AV. Kliniko-epidemiologicheskaya kharakteristika gemoblastozov v Respublike Bashkortostan. (Clinical and epidemiological characteristics of hemoblastosis in the Republic of Bashkortostan.) [dissertation] Ufa; 2011. (In Russ)]

  7. Рябчикова Н.Р., Минниахметов И.Р, Сафуанова Г.Ш. и др. Хронический миелолейкоз: молекулярный мониторинг в клинической практике. Онкогематология. 2013;8(1):1–16. doi: 10.17650/1818-8346-2013-8-1-7-16.

    [Ryabchikova NR, Minniakhmetov IR, Safuanova GSh, et al. Chronic myeloid leukemia: molecular monitoring in clinical practice. Onkogematologiya. 2013;8(1):1–16. doi: 10.17650/1818-8346-2013-8-1-7-16. (In Russ)]

  8. Куликов С.М., Виноградова О.Ю., Челышева Е.Ю. и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009–2012 гг. Терапевтический архив. 2014;86(7):24–30.

    [Kulikov SM, Vinogradova OYu, Chelysheva EYu, et al. Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009–2012 population-based study. Terapevticheskii arkhiv. 2014;86(7):24–30. (In Russ)]

  9. Туркина А.Г., Голенков А.К., Напсо Л.И. и др. Российский регистр по лечению хронического миелоидного лейкоза в рутинной клинической практике: итоги многолетней работы. Эффективная фармакотерапия. 2015;10(1):8–13.

    [Turkina AG, Golenkov AK, Napso LI, et al. The Russian registry of chronic myeloid leukemia treatment in routine clinical practice: results of the long-term work. Effektivnaya farmakoterapiya. 2015;(10):8–13. (In Russ)]

  10. Волкова С.А., Ковалишена О.В., Гостюжова Е.А. и др. Эффект от терапии иматинибом по данным клинико-эпидемиологического мониторинга хронического миелолейкоза в Нижегородской области за период 2000–2010 г. Гематология и трансфузиология. 2011;56(4):17–22.

    [Volkova SA, Kovalishena OV, Gostyuzhova EA, et al. Imatinib therapy effect according to the results of clinical and epidemiological monitoring of chronic myeloid leukemia in the Nizhny Novgorod region over the period of 2000–2010. Gematologiya i transfuziologiya. 2011;56(4):17–22. (In Russ)]

Organization of specialized medical care for patients with blood disorders in Saint Petersburg

ORGANIZATION OF PUBLIC HEALTH , , , , , , , , , ,

L.U. Zhiguleva and К.М. Abdulkadyrov

Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation

ABSTRACT

Over the past decade, the significant progress was achieved in the outcomes of treatment of blood disorders that reflects not only the advances in the medicine as a whole, but also in molecular biology, chemistry, genetics, nanotechnologies, etc. The rational organization is the key factor for the increased efficacy of specialized medical care. This article includes analysis of the structure, organization, and results of the work of St Petersburg hematological institutions and their influence on the city population health parameters in 2000–2012. The importance of the system approach to the organization of hematological care is also noted. The findings are the decreased mortality from malignancies of hematopoietic, lymphoid, and related tissues, increased their incidence (prevalence) due to increased mean life expectancy of patients, increased 5-year survival rate, decreased total and 1st-year mortality after the diagnosis. The weak link of the hematological care was identified, i.e. insufficient knowledge of hematology among general medical practitioners and pediatricians. The need for further research of personnel workload adequacy and its influence on of hematological care quality is indicated.

Keywords: morbidity, mortality, lethality, hematological care, blood disorders, malignancies of hematopoietic, lymphoid, and related tissues, out-patients-based follow-up, hematopoietic stem cells transplantation, high-tech medical care.

Read in PDF (RUS)pdficon

REFERENCE

  1. Baccarani M., Deininger M.W., Rosti G. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872–884 ,
  2. Experts in Chronic Myeloid L. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121(22): 4439–42.
  3. Hehlmann R., Heimpel H., Hasford J. et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 1993; 82: 398–407.
  4. Chronic Myeloid Leukemia Trialists’ Collaborative G. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data metaanalysis of three randomized trials. Br. J. Haematol. 2000; 110: 573–6.
  5. Italian Cooperative Study Group On Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 1994; 330(12): 820–5.
  6. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists’ Collaborative Group. J. Natl. Cancer Inst. 1997; 89(21): 1616–20.
  7. Thomas D.E., Clift R.A., Fefer A. et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann. Intern. Med. 1986; 104: 155–63.
  8. Hansen J.A., Gooley T.A., Martin P.J. et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N. Engl. J. Med. 1998; 338: 962–8.
  9. Hehlmann R. A chance of cure for every patient with chronic myeloid leukemia? N. Engl. J. Med. 1998; 338(14): 980–2.
  10. Druker B.J., Guilhot F., O’Brien S.G. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006; 355(23): 2408–17.
  11. Donohue B. Investigator’s Broschure: Clinical Development — STI571 (formerly CGP 57148B) — Imatinib mesylate. Novartis Edition 15; 2013.
  12. Hehlmann R., Lauseker M., Jung-Munkwitz S. et al. Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-alpha in Newly Diagnosed Chronic Myeloid Leukemia. J. Clin. Oncol. 2011; 29(12): 1634–42.
  13. Gambacorti-Passerini C., Antolini L., Mahon F.X. et al. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. J. Natl. Cancer Inst. 2011; 103(7): 553–61.
  14. Deininger M., O’Brien S.G., Guilhot F. et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH Annual Meeting Abstracts 2009; 114(22): 1126.
  15. Soverini S., Hochhaus A., Nicolini F.E. et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118(5): 1208–15.
  16. Kantarjian H.M., Shah N.P., Cortes J.E. et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119(5): 1123–9.
  17. Larson R.A., Hochhaus A., Hughes T.P. et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26(10): 2197–203.
  18. Cortes J.E., Jones D., O’Brien S. et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol. 2010; 28(3): 392–7.
  19. Rosti G., Palandri F., Castagnetti F. et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114(24): 4933–8.
  20. Cortes J.E., Kim D.W., Kantarjian H.M. et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J. Clin. Oncol. 2012; 30(28): 3486–92.
  21. Cortes J.E., Jones D., O’Brien S. et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 2010; 28(3): 398–404.
  22. Hochhaus A., Saglio G., Larson R.A. et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013; 121(18): 3703–8.
  23. Cortes J., Giles F., O’Brien S. et al. Results of high-dose imatinib mesylate in patients with Philadelphia chromosome positive chronic myeloid leukemia after failure of interferon-alfa. Blood 2003; 102: 83–6.
  24. Kantarjian H., Talpaz M., O’Brien S. et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–8.
  25. Cortes J.E., Kantarjian H.M., Goldberg S.L. et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J. Clin. Oncol. 2009; 27(28): 4754–9.
  26. Hughes T.P., Branford S., White D.L. et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008; 112(10): 3965–73.
  27. Cortes J.E., Baccarani M., Guilhot F. et al. Phase III, randomized, openlabel study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 2010; 28(3): 424–30.
  28. Montani D., Bergot E., Guenther S. et al. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation 2012; 125(17): 2128–37.
  29. Giles F.J., Mauro M.J., Hong F. et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310–5.
  30. Kim T.D., Rea D., Schwarz M. et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27(6): 1316–21.
  31. Sokal J.E., Cox E.B., Baccarani M. et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63(4): 789–99.
  32. Hasford J., Pfirrmann M., Hehlmann R. et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J. Natl. Cancer Inst. 1998; 90(11): 850–8.
  33. Hasford J., Baccarani M., Hoffmann V. et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118(3): 686–92.
  34. Fabarius A., Leitner A., Hochhaus A. et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118(26): 6760–8.
  35. Hanfstein B., Müller M.C., Hehlmann R. et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26(9): 2096–102.
  36. Marin D., Ibrahim A.R., Lucas C. et al. Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. J. Clin. Oncol. 2012; 30(3): 232–8.
  37. Hehlmann R., Müller M.C., Lauseker M. et al. Deep Molecular Response (MR4.5) is reached by the majority of imatinib-treated patients, predicts survival, and is achieved faster by optimized high-dose imatinib — results from the randomized CML-Study IV. J. Clin. Oncol. 2014; 32: 415–423.
  38. Saussele S., Lauseker M., Gratwohl A. et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115(10): 1880–5.
  39. Saglio G., Kim D.W., Issaragrisil S. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010; 362(24): 2251–9.
  40. Kantarjian H., Shah N.P., Hochhaus A. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2010; 362(24): 2260–70.
  41. Hehlmann R. How I treat CML blast crisis. Blood 2012; 120(4): 737–47.
  42. Saglio G., Kantarjian H.M., Shah N. et al. Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. ASH Annual Meeting Abstracts 2012; 120(21): 1675.
  43. Hochhaus A., Hughes T.P., Saglio G. et al. Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). ASH Annual Meeting Abstracts 2012; 120(21): 167.
  44. Mahon F.X., Rea D., Guilhot J. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11): 1029–35.
  45. Ross D.M., Branford S., Seymour J.F. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122(4): 515–22.
  46. Branford S., Yeung D.T., Ross D.M. et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013; 121(19): 3818–24.